Qiagen N.V. - ADR Peer Comparison
$45.06
$-0.59
(-1.29%)
As on 07-Oct-2026 14:40EDT
Market cap
$8,681 Mln
Revenue (TTM)
$2,100 Mln
P/E Ratio
22.2
P/B Ratio
2.7
Div. Yield
0.8 %
Edit
| Qiagen N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | ProQR Therapeutics N.V. - ADR | ATAI Life Sciences BV (ATAI) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
8,681 | 2,190 | 1,627 | 231 | 2,726 |
Revenue ($ Mln) |
2,100 | -- | 19 | 19 | 4 |
Net Profit ($ Mln) |
409.32 | -171.57 | -252.21 | -42.32 | -668.19 |
Net Margin (%) |
19.49 | -- | -1,350.73 | -228.38 | -14,938.37 |
RoE (%) |
11.47 | -59.98 | -96.46 | -65.71 | -335.53 |
Price to Earnings |
22.24 | -- | -- | -- | -- |
Price-To-Book |
2.69 | 6.74 | 9.15 | 2.63 | 15.46 |
Cashflow ($ Mln)
| Qiagen N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | ProQR Therapeutics N.V. - ADR | ATAI Life Sciences BV (ATAI) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
654.33 | -137.07 | -177.96 | -52.79 | -102.68 |
|
Cash Flow from Investing Activities
|
-305.28 | -0.16 | -321.62 | -1.02 | -109.13 |
|
Cash from Financing Activities
|
-178.98 | 160.61 | 415.40 | -1.84 | 269.48 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Qiagen N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | ProQR Therapeutics N.V. - ADR | ATAI Life Sciences BV (ATAI) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
8.01 | -64.99 | -50.07 | -44.48 | -361.72 |
|
ROE (%)
|
11.47 | -59.98 | -96.46 | -65.71 | -335.53 |
|
ROA (%)
|
6.10 | -58.07 | -29.77 | -22.01 | -263.03 |
|
EBIT Margin (%)
|
23.80 | -- | -1,047.15 | -229.99 | -15,198.77 |
|
Net Margin (%)
|
19.49 | -- | -1,350.73 | -228.38 | -14,938.37 |
|
Cash Profit Margin (%)
|
0.00 | -- | 0.00 | 0.00 | -0.02 |
Growth Ratios
| Qiagen N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | ProQR Therapeutics N.V. - ADR | ATAI Life Sciences BV (ATAI) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
2.96 | -- | 30.24 | 12.40 | 93.72 |
|
EBIT Growth (%)
|
-4.99 | -35.87 | -44.77 | -13.38 | -530.01 |
|
Net Profit Growth (%)
|
9.62 | -1.94 | -26.74 | -6.67 | -459.61 |
|
EPS Growth (%)
|
14.23 | 15.07 | -4.52 | 6.83 | -316.60 |
|
Book Value Growth (%)
|
0.56 | 31.10 | 6,797.66 | -3.20 | -33.14 |
Valuation Ratios
| Qiagen N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | ProQR Therapeutics N.V. - ADR | ATAI Life Sciences BV (ATAI) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
21.99 | -10.30 | -6.92 | -5.14 | -1.38 |
|
Price / Book Value
|
2.47 | 6.67 | 6.92 | 3.59 | 4.09 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
13.80 | -8.76 | -11.07 | -3.13 | -0.99 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Qiagen N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | ProQR Therapeutics N.V. - ADR | ATAI Life Sciences BV (ATAI) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.48 | 0.00 | 0.15 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.00 | 0.00 | 0.01 | 0.06 | 0.02 |
|
Current Ratio
|
2.85 | 11.94 | 10.01 | 3.49 | 8.58 |
|
Quick Ratio
|
2.31 | 11.94 | 10.01 | 3.49 | 8.58 |
|
Interest Coverage
|
12.71 | -1,045.90 | -3.11 | -45.75 | -334,090.00 |
Operating Efficiency Ratios
| Qiagen N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | ProQR Therapeutics N.V. - ADR | ATAI Life Sciences BV (ATAI) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
19.00 | -- | 30.94 | 10.03 | 14.46 |
|
Asset Turnover
|
0.31 | 0.00 | 0.02 | 0.10 | 0.02 |
|
Receivable days
|
75.29 | -- | 133.23 | 96.49 | 704.55 |
|
Inventory Days
|
132.91 | -- | 0.00 | -- | -- |
|
Payable days
|
35.66 | -- | 1,342.82 | 25.78 | 1,357.42 |
|
Cash Conversion Cycle
|
172.54 | -- | -1,209.59 | -- | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
